Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-Cycloserine for Social Phobia
NCT00128401Phase 2Completed
- Sponsor
- National Institute of Mental Health
- Start
- Aug 2005
- Primary completion
- Jun 2012
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of d-cycloserine in Social Anxiety Disorder (SAD), sponsored by National Institute of Mental Health. Primary endpoint: Clinical Global Improvement Severity at 12 weeks. Started Aug 2005; status: completed.
02
Drugs
d-cycloserine
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT00128401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00128401.